Want to join the conversation?
Gabelli analyst Rosemarie Morbelli questions $SHLM whether there was some voluntary elimination of product lines that resulted in the legacy decline. CEO Bernard Rzepka says that the company participates in the Distribution business only if it's able to make money. $SHLM is exiting Commodity businesses and focusing on Specialty business.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.